Suppr超能文献

真实环境下接受根治性放疗的非小细胞肺癌患者的健康相关生活质量和毒性概述(REQUITE 研究)。

Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).

机构信息

Department of Radiation Oncology, Ghent University Hospital and Ghent University, Ghent, Belgium.

Fundación Pública Galega de Medicina Xenómica, Grupo de Medicina Xenómica (USC), Santiago de Compostela, Spain.

出版信息

Lung Cancer. 2022 Apr;166:228-241. doi: 10.1016/j.lungcan.2022.03.010. Epub 2022 Mar 15.

Abstract

OBJECTIVES

Radiotherapy-induced toxicity may negatively impact health-related quality of life (HRQoL). This report investigates the impact of curative-intent radiotherapy on HRQoL and toxicity in early stage and locally-advanced non-small cell lung cancer patients treated with radiotherapy or chemo-radiotherapy enrolled in the observational prospective REQUITE study.

MATERIALS AND METHODS

HRQoL was assessed using the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire up to 2 years post radiotherapy. Eleven toxicities were scored by clinicians using the Common Terminology Criteria for Adverse Events (CTCAE) version 4. Toxicity scores were calculated by subtracting baseline values. Mixed model analyses were applied to determine statistical significance (p ≤ 0.01). Meaningful clinical important differences (MCID) were determined for changes in HRQoL. Analysis was performed on the overall data, different radiotherapy techniques, multimodality treatments and disease stages.

RESULTS

Data of 510 patients were analysed. There was no significant change in HRQoL or its domains, except for deterioration in cognitive functioning (p = 0.01). Radiotherapy technique had no significant impact on HRQoL. The addition of chemotherapy was significantly associated with HRQoL over time (p <.001). Overall toxicity did not significantly change over time. Acute toxicities of radiation-dermatitis (p =.003), dysphagia (p =.002) and esophagitis (p <.001) peaked at 3 months and decreased thereafter. Pneumonitis initially deteriorated but improved significantly after 12 months (p =.011). A proportion of patients experienced meaningful clinically important improvements and deteriorations in overall HRQoL and its domains. In some patients, pre-treatment symptoms improved gradually.

CONCLUSIONS

While overall HRQoL and toxicity did not change over time, some patients improved, whereas others experienced acute radiotherapy-induced toxicities and deteriorated HRQoL, especially physical and cognitive functioning. Patient characteristics, more so than radiotherapy technique and treatment modality, impact post-radiotherapy toxicity and HRQoL outcomes. This stresses the importance of considering the potential impact of radiotherapy on individuals' HRQoL, symptoms and toxicity in treatment decision-making.

摘要

目的

放疗引起的毒性可能会对健康相关生活质量(HRQoL)产生负面影响。本报告调查了在接受放疗或放化疗的早期和局部晚期非小细胞肺癌患者中,根治性放疗对 HRQoL 和毒性的影响,这些患者来自观察性前瞻性 REQUITE 研究。

材料和方法

在放疗后 2 年内,使用欧洲癌症研究与治疗组织(EORTC) QLQ-C30 问卷评估 HRQoL。11 种毒性由临床医生使用不良事件通用术语标准(CTCAE)版本 4 进行评分。毒性评分通过减去基线值计算。应用混合模型分析确定统计学意义(p≤0.01)。确定 HRQoL 变化的有意义的临床重要差异(MCID)。对整体数据、不同放疗技术、多模态治疗和疾病阶段进行了分析。

结果

共分析了 510 名患者的数据。除认知功能恶化(p=0.01)外,HRQoL 或其各领域均无显著变化。放疗技术对 HRQoL 没有显著影响。化疗的加入与随时间推移的 HRQoL 显著相关(p<.001)。总体毒性随时间没有显著变化。急性放射性皮炎(p=0.003)、吞咽困难(p=0.002)和食管炎(p<.001)的毒性在 3 个月时达到峰值,此后逐渐下降。肺炎最初恶化,但 12 个月后显著改善(p=0.011)。一些患者的整体 HRQoL 及其各领域出现了有意义的临床重要改善和恶化。在一些患者中,治疗前的症状逐渐改善。

结论

尽管整体 HRQoL 和毒性随时间没有变化,但一些患者得到改善,而另一些患者则经历了急性放疗引起的毒性和 HRQoL 恶化,特别是身体和认知功能。患者特征,而不是放疗技术和治疗方式,对放疗后毒性和 HRQoL 结果有影响。这强调了在治疗决策中考虑放疗对个体 HRQoL、症状和毒性潜在影响的重要性。

相似文献

3
Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study.
Front Oncol. 2021 Jun 17;11:685605. doi: 10.3389/fonc.2021.685605. eCollection 2021.
8
High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL.
Radiother Oncol. 2009 Jun;91(3):443-8. doi: 10.1016/j.radonc.2009.02.010. Epub 2009 Mar 16.
10
Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings.
Clin Lung Cancer. 2018 Mar;19(2):139-147. doi: 10.1016/j.cllc.2017.10.003. Epub 2017 Oct 13.

本文引用的文献

2
The use of patient reported outcome measures (PROMs) in palliative radiotherapy: A topical review.
Radiother Oncol. 2020 Aug;149:94-103. doi: 10.1016/j.radonc.2020.04.045. Epub 2020 Apr 29.
5
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
J Thorac Oncol. 2020 Feb;15(2):288-293. doi: 10.1016/j.jtho.2019.10.002. Epub 2019 Oct 14.
8
REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer.
Radiother Oncol. 2019 Sep;138:59-67. doi: 10.1016/j.radonc.2019.04.034. Epub 2019 May 27.
9
Changes in quality of life after surgery or radiotherapy in early-stage lung cancer.
J Thorac Dis. 2019 Jan;11(1):154-161. doi: 10.21037/jtd.2018.12.30.
10
Radiotherapy toxicity.
Nat Rev Dis Primers. 2019 Feb 21;5(1):13. doi: 10.1038/s41572-019-0064-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验